As of November 10, 2020
Considering the management performance and financial condition overall, Takara Bio recognizes a basic policy aimed for profit contribution, positioning the profit distribution to shareholders as an important issue for management as well as enhancing the internal reserves to strengthen the R&D activities of three business segments: Bioindustry, Gene Therapy, and AgriBio businesses.
Specifically, our policy calls for a target rate of around 20% of estimated profit calculated without considering extraordinary income or loss in the consolidated financial statements.
|Dividend Per Share(yen)||1Q||-||-||-||-||-||-|
|Amount of Dividends(million yen)||541||842||963||1,926||3,973||-|
|Ratio of Total Amount of Dividends to Net Assets(%)||0.9||1.3||1.5||2.7||4.7||-|
We have not bought back our shares as of today.